Completed NA INTERVENTIONAL 2-arm NCT00700128

Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals (MAM)

Prevention of Menstrual Migraines: Effects of Continuous Oral Contraceptives to Combination With Prophylactic Frovatriptan Use During Hormone Free Intervals

Sponsor: Endo Pharmaceuticals

Conditions Bleeding Migraines Spotting

Interventions frovatriptan placebo

Updated 5 times since 2017 Last updated: Jul 22, 2011 Started: Jun 30, 2008 Primary completion: Jan 31, 2010 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Bleeding and Migraines and is currently completed. Endo Pharmaceuticals leads this study, which shows 5 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Endo Pharmaceuticals
Scott and White Hospital & Clinic

Data source: Scott and White Hospital & Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Temple, United States